- Home
- IBRX vs IRON Comparison
IBRX vs IRON Comparison
Compare IBRX & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- IRON
- Stock Information
- Founded
- IBRX 2014
- IRON 2017
- Country
- IBRX United States
- IRON United States
- Employees
- IBRX N/A
- IRON N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- IBRX Health Care
- IRON Health Care
- Exchange
- IBRX Nasdaq
- IRON Nasdaq
- Market Cap
- IBRX 2.3B
- IRON 2.1B
- IPO Year
- IBRX N/A
- IRON N/A
- Fundamental
- Price
- IBRX $2.58
- IRON $87.61
- Analyst Decision
- IBRX Strong Buy
- IRON Strong Buy
- Analyst Count
- IBRX 6
- IRON 12
- Target Price
- IBRX $9.83
- IRON $103.33
- AVG Volume (30 Days)
- IBRX 9.7M
- IRON 619.2K
- Earning Date
- IBRX 11-10-2025
- IRON 11-11-2025
- Dividend Yield
- IBRX N/A
- IRON N/A
- EPS Growth
- IBRX N/A
- IRON N/A
- EPS
- IBRX N/A
- IRON N/A
- Revenue
- IBRX $56,600,000.00
- IRON N/A
- Revenue This Year
- IBRX $629.94
- IRON N/A
- Revenue Next Year
- IBRX $109.91
- IRON N/A
- P/E Ratio
- IBRX N/A
- IRON N/A
- Revenue Growth
- IBRX 4227.22
- IRON N/A
- 52 Week Low
- IBRX $1.83
- IRON $30.82
- 52 Week High
- IBRX $6.82
- IRON $95.95
- Technical
- Relative Strength Index (RSI)
- IBRX 54.54
- IRON 68.28
- Support Level
- IBRX $2.30
- IRON $83.52
- Resistance Level
- IBRX $2.67
- IRON $89.00
- Average True Range (ATR)
- IBRX 0.12
- IRON 3.73
- MACD
- IBRX 0.01
- IRON 0.85
- Stochastic Oscillator
- IBRX 75.68
- IRON 69.26
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.